Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1991 2
1992 2
1993 1
1994 1
1995 3
1996 1
1997 2
1999 2
2000 1
2001 2
2003 2
2004 6
2005 4
2006 2
2007 2
2008 2
2009 7
2010 8
2011 5
2012 10
2013 11
2014 17
2015 17
2016 12
2017 13
2018 17
2019 14
2020 19
2021 25
2022 22
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Cerebral cavernous malformation 4"
Page 1
Somatic MAP3K3 and PIK3CA mutations in sporadic cerebral and spinal cord cavernous malformations.
Hong T, Xiao X, Ren J, Cui B, Zong Y, Zou J, Kou Z, Jiang N, Meng G, Zeng G, Shan Y, Wu H, Chen Z, Liang J, Xiao X, Tang J, Wei Y, Ye M, Sun L, Li G, Hu P, Hui R, Zhang H, Wang Y. Hong T, et al. Brain. 2021 Oct 22;144(9):2648-2658. doi: 10.1093/brain/awab117. Brain. 2021. PMID: 33729480
Cavernous malformations affecting the CNS occur in 0.16-0.4% of the general population. The majority (85%) of cavernous malformations are in a sporadic form, but the genetic background of sporadic cavernous malformations remains enigmatic. ...
Cavernous malformations affecting the CNS occur in 0.16-0.4% of the general population. The majority (85%) of cavernous …
Clinical characteristics and long-term outcome of cerebral cavernous malformations-related epilepsy.
Shih YC, Chou CC, Peng SJ, Yu HY, Hsu SPC, Lin CF, Lee CC, Yang HC, Chen YC, Kwan SY, Chen C, Wang SJ, Lin CJ, Lirng JF, Shih YH, Yen DJ, Liu YT. Shih YC, et al. Epilepsia. 2022 Aug;63(8):2056-2067. doi: 10.1111/epi.17309. Epub 2022 Jun 14. Epilepsia. 2022. PMID: 35593439
OBJECTIVE: Cerebral cavernous malformations (CCMs) present variably, and epileptic seizures are the most common symptom. ...The most common lesion site in the DRE group was the mesiotemporal lobe (50%). Multiple CCMs were more frequently observed in the CRE ( …
OBJECTIVE: Cerebral cavernous malformations (CCMs) present variably, and epileptic seizures are the most common symptom. ...Th …
Cerebral cavernous malformations: natural history and clinical management.
Gross BA, Du R. Gross BA, et al. Expert Rev Neurother. 2015;15(7):771-7. doi: 10.1586/14737175.2015.1055323. Epub 2015 Jun 22. Expert Rev Neurother. 2015. PMID: 26098013 Review.
Cavernous malformations (CMs) are angiographically-occult clusters of dilated sinusoidal channels that may present clinically with seizures, focal neurological deficits and/or hemorrhage. ...Incidental CMs or minimally symptomatic, surgically inaccessible eloquent lesions …
Cavernous malformations (CMs) are angiographically-occult clusters of dilated sinusoidal channels that may present clinically with se …
Brainstem cavernous malformations.
Petr O, Lanzino G. Petr O, et al. J Neurosurg Sci. 2015 Sep;59(3):271-82. Epub 2015 May 6. J Neurosurg Sci. 2015. PMID: 25943871 Free article. Review.
Of all cavernous malformations (CMs), 4% to 35% are found in the brainstem accounting for 13% of vascular malformations of the posterior fossa. ...Over the years, we have taken a more cautious stance and we often recommend observation in patients after a sing …
Of all cavernous malformations (CMs), 4% to 35% are found in the brainstem accounting for 13% of vascular malformations of the …
Cerebral cavernous malformation: Management and outcome during pregnancy and puerperium. A systematic review of literature.
Merlino L, Del Prete F, Titi L, Piccioni MG. Merlino L, et al. J Gynecol Obstet Hum Reprod. 2021 Jan;50(1):101927. doi: 10.1016/j.jogoh.2020.101927. Epub 2020 Oct 6. J Gynecol Obstet Hum Reprod. 2021. PMID: 33035718
INTRODUCTION: Cerebral cavernomas malformations (CCMs) are vascular malformations that occur with an incidence of 0,4-0,8 % in general population. The most feared complication is cerebral hemorrhage. Currently there are no guidelines for pregnant women with C …
INTRODUCTION: Cerebral cavernomas malformations (CCMs) are vascular malformations that occur with an incidence of 0,4-0,8 % in …
Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation.
Weinsheimer S, Nelson J, Abla AA, Ko NU, Tsang C, Okoye O, Zabramski JM, Akers A, Zafar A, Mabray MC, Hart BL, Morrison L, McCulloch CE, Kim H; Brain Vascular Malformation Consortium Cerebral Cavernous Malformation Investigator Group *. Weinsheimer S, et al. J Am Heart Assoc. 2023 Feb 7;12(3):e027572. doi: 10.1161/JAHA.122.027572. Epub 2023 Jan 25. J Am Heart Assoc. 2023. PMID: 36695309 Free PMC article.
Background Familial cerebral cavernous alformation (CCM) is an autosomal dominant disease caused by mutations in KRIT1, CCM2, or PDCD10. ...The symptomatic ICH rate for familial CCM cases was 2.8 per 100 patient-years (95% CI, 1.9-4.1). Those with ICH before …
Background Familial cerebral cavernous alformation (CCM) is an autosomal dominant disease caused by mutations in KRIT1, CCM2, …
Bleeding risk evaluation in cerebral cavernous malformation, the role of medications, and hemorrhagic factors: a case-control study.
Scerrati A, Mantovani G, Travaglini F, Bradaschia L, De Bonis P, Farneti M, Cavallo MA, Dones F, Flacco ME, Auricchio AM, Benato A, Albanese A, Sturiale CL. Scerrati A, et al. Neurosurg Focus. 2023 Oct;55(4):E15. doi: 10.3171/2023.7.FOCUS23355. Neurosurg Focus. 2023. PMID: 37778034
OBJECTIVE: Cerebral cavernous malformations (CCMs) are vascular lesions with an overall risk of rupture from 2% to 6% per year, which is associated with significant morbidity and mortality. ...METHOD: This was a multicenter retrospective observational study. …
OBJECTIVE: Cerebral cavernous malformations (CCMs) are vascular lesions with an overall risk of rupture from 2% to 6% per year …
Clinical characteristics of familial and sporadic pediatric cerebral cavernous malformations and outcomes.
Jaman E, Abdallah HM, Zhang X, Greene S. Jaman E, et al. J Neurosurg Pediatr. 2023 Jul 21;32(4):506-513. doi: 10.3171/2023.5.PEDS22397. Print 2023 Oct 1. J Neurosurg Pediatr. 2023. PMID: 37503918
OBJECTIVE: Cerebral cavernous malformation (CCM) is a subtype of the vascular malformations found within the cerebral cortex. ...Multivariate analysis was performed using a Cox proportional hazards model with R version 4.2.0. RESULTS: This retro …
OBJECTIVE: Cerebral cavernous malformation (CCM) is a subtype of the vascular malformations found within the cerebra …
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
Lanfranconi S, Scola E, Meessen JMTA, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R; Treat_CCM Investigators. Lanfranconi S, et al. Lancet Neurol. 2023 Jan;22(1):35-44. doi: 10.1016/S1474-4422(22)00409-4. Epub 2022 Nov 17. Lancet Neurol. 2023. PMID: 36403580 Free article. Clinical Trial.
People aged 18 years or older with symptomatic familial cerebral cavernous malformation were eligible for enrolment. Participants were randomly assigned (2:1) to receive either oral propranolol (20-320 mg daily) plus standard care (intervention group), or sta …
People aged 18 years or older with symptomatic familial cerebral cavernous malformation were eligible for enrolment. Pa …
Quality of life and mood assessment in conservatively treated cavernous malformation-related epilepsy.
Rauschenbach L, Bartsch P, Santos AN, Lenkeit A, Darkwah Oppong M, Wrede KH, Jabbarli R, Chmielewski WX, Schmidt B, Quesada CM, Forsting M, Sure U, Dammann P. Rauschenbach L, et al. Brain Behav. 2022 Jun;12(6):e2595. doi: 10.1002/brb3.2595. Epub 2022 Apr 25. Brain Behav. 2022. PMID: 35470577 Free PMC article.
BACKGROUND: To estimate the quality of life, anxiety, depression, and illness perception in patients with medically treated cerebral cavernous malformation (CCM) and associated epilepsy. METHODS: Nonsurgically treated patients with CCM-related epilepsy (CRE) …
BACKGROUND: To estimate the quality of life, anxiety, depression, and illness perception in patients with medically treated cerebral …
217 results